Ribonucleotide reductase inhibitors and methods of use
USRE45020E1 · kind E1 · reissue
4Cited by
0References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 5, 2013 |
| Grant date | Jul 15, 2014 |
| Priority date | — |
| Expiry date | Aug 5, 2033 |
Classification
- Technology area (CPC —)General
Abstract
Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.